Fulgent Genetics, Inc. filings document operating results, business updates, governance matters, capital-structure activity, and clinical disclosures for a company with laboratory services and therapeutic development operations. Form 8-K reports furnish earnings releases, investor presentation updates, stock repurchase activity, and material-event disclosures tied to the company's business and pipeline.
The company's proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and other governance disclosures. Clinical and regulatory filings include updates related to FID-007 in recurrent or metastatic head and neck squamous cell carcinoma, while broader disclosures address financial performance, risk, and capital allocation.
Fulgent Genetics (FLGT) filed a Form 4 showing that CFO & Treasurer Paul Kim had 2,743 common shares withheld on 07/26/2025 to cover taxes upon the vesting of RSUs tied to the 2022 Fulgent Pharma merger. The transaction was coded “F,” meaning it was an automatic, non-discretionary share surrender for tax withholding, not an open-market sale. The shares were valued at an implied $18.37 each (company-supplied price).
After the withholding, Kim directly owns 339,828 shares, so his economic exposure fell by <1 %. No derivative securities were exercised or disposed of, and no cash changed hands. Because the disposition is routine and immaterial relative to Kim’s total stake, the filing is largely neutral for investors and does not alter the company’s fundamental outlook.